Up Up Up
$Novavax (NVAX.US)$
Novavax Says NVX-COV2373 Demonstrated Overall Efficacy Of ~90% In Prevent-19 Clinical Trial Conducted During Emergence Of Variant Strains
Novavax Says NVX-COV2373 Demonstrated Overall Efficacy Of ~90% In Prevent-19 Clinical Trial Conducted During Emergence Of Variant Strains
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
价值投资是王道 OP : Novavax Inc. submitted a request Monday to the U.S. Food and Drug Administration for Emergency Use Authorization for Covid-19 vaccine candidate NVX-CoV2373, for people 18 and up.